News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NuVasive, Inc. (NUVA) Management To Participate In Investor Events In May And June 2014


5/8/2014 8:39:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, CA--(Marketwired - May 07, 2014) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that management will participate in the following investor events in May and June 2014:

  • The Bank of America Merrill Lynch Healthcare Conference at the Encore at Wynn in Las Vegas, Nevada, on Thursday, May 15, 2014, at 9:20am PT

  • The Goldman Sachs 35th Annual Global Healthcare Conference at the Terranea Resort in Ranchos Palos Verdes, California, on Tuesday, June 10, 2014, at 10:00am PT

  • The William Blair Growth Stock Conference at the Four Seasons Hotel in Chicago, Illinois, on Wednesday, June 11, 2014, at 8:40am CT

A live webcast of each of the formal presentations will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, a replay of each presentation will remain available on the website for 30 days.

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.7 billion global spine market.

NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game-changing technology such as the XLIF Decade™ plate for single-approach fixation through a lateral incision, the PCM® motion-preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and the Armada® posterior fixation system, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedurally integrated solutions that completely redefine and improve upon traditional techniques like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation, and Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release or by management when participating in the above-described investor events that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of our network of sales representatives, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.


Investor Contact:
Tina Jacobsen
NuVasive, Inc.
858-320-5215
Email Contact

Media Contact:
Nicole Collins
NuVasive, Inc.
858-909-1907
Email Contact



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES